TG Therapeutics, Inc.
HealthcareNASDAQ:TGTX · NASDAQ Capital Market
+$1.47 today
Vol 2.53M · Avg 2.09M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$700.3M of revenue converted into $461.9M of net income for the selected period. Gross margin is 83.3% and net margin is 70.8%, showing how much revenue survives after costs and taxes. EPS is $2.86, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $616.3M +87.3% | $329.0M +40.8% | $233.7M +8290.0% | $2.8M -58.4% | $6.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $100.7M +161.7% | $38.5M +172.4% | $14.1M +5232.5% | $265.0K -66.5% | $790.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $515.6M +77.5% | $290.5M +32.3% | $219.5M +8611.5% | $2.5M -57.3% | $5.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 83.7% -4.6pp | 88.3% -5.7pp | 94.0% +3.5pp | 90.5% +2.3pp | 88.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $160.2M +69.9% | $94.3M +23.8% | $76.2M -39.2% | $125.4M -43.7% | $222.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $232.0M +50.4% | $154.3M +25.7% | $122.7M +28.5% | $95.5M -25.5% | $128.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $392.2M +57.8% | $248.6M +25.0% | $198.9M -9.9% | $220.8M -37.0% | $350.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $244.0K -12.9% | $280.0K -33.8% | $423.0K -17.9% | $515.0K +4.3% | $494.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $134.4M +169.2% | $49.9M +91.2% | $26.1M +112.2% | -$213.1M +37.7% | -$342.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 21.8% +6.6pp | 15.2% +4.0pp | 11.2% +7663.1pp | -7651.9% -2539.5pp | -5112.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $123.3M +194.1% | $41.9M +103.2% | $20.6M +109.5% | -$218.3M +36.7% | -$344.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 20.0% +7.3pp | 12.7% +3.9pp | 8.8% +7847.8pp | -7839.0% -2684.7pp | -5154.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $26.7M +11.2% | $24.0M +90.5% | $12.6M +23.8% | $10.2M +80.8% | $5.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$15.9M +2.5% | -$16.3M -115.8% | -$7.6M -37.8% | -$5.5M -65.0% | -$3.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $107.4M +319.6% | $25.6M +95.9% | $13.1M +105.8% | -$223.8M +35.7% | -$348.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 17.4% +9.6pp | 7.8% +2.2pp | 5.6% +8041.9pp | -8036.3% -2832.3pp | -5204.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$339.8M -15468.1% | $2.2M +466.9% | $390.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $447.2M +1812.4% | $23.4M +84.5% | $12.7M +105.7% | -$223.8M +35.7% | -$348.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 72.6% +65.5pp | 7.1% +1.7pp | 5.4% +8041.8pp | -8036.3% -2832.3pp | -5204.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +1837.5% | $0 +79.2% | $0 +106.1% | -$1 +44.5% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +1746.7% | $0 +75.8% | $0 +105.8% | -$1 +44.5% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $144.3M -0.7% | $145.3M +2.4% | $142.0M +4.8% | $135.4M +2.4% | $132.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $161.4M +0.7% | $160.3M +8.0% | $148.5M +9.7% | $135.4M +2.4% | $132.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.37B
Alkermes plc
NASDAQ:ALKS
$7.38B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.06B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.23B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TGTX generate?
TG Therapeutics, Inc. (TGTX) reported $616.29M of revenue in fiscal 2025.
Is TGTX profitable?
TG Therapeutics, Inc. (TGTX) reported $447.18M of net income, with a net margin of 72.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.